|
|
High-risk patients |
Induction therapy |
Cycle 1 |
|
Cytarabine |
Days 1–7: |
Cytarabine 100 mg/m2/day continuous intravenous (IV) infusion for 2 h |
Daunorubicin |
Days 1, 3 and 5: |
Daunorubicin 30 mg/m2/day continuous IV infusion for 1 h |
Etoposide |
Days 1–5: |
Etoposide 100 mg/m2/day IV for 3 h |
Mitoxantrone |
Day 2: |
Intrathecal (IT) chemotherapy (Table II) |
|
Cycle 2 |
|
|
Days 1–7: |
Cytarabine 100 mg/m2/day continuous IV infusion for 2 h |
|
Days 1, 3. 5: |
Daunorubicin 30 mg/m2/day continuous IV infusion for 1 h |
|
Days 1–5: |
Etoposide 100 mg/m2/day continuous IV infusion for 3 h |
|
Day 2: |
IT chemotherapy (Table II) |
|
Cycle 3 |
|
|
Days 1–5: |
Cytarabine 100 mg/m2/day continuous IV infusion for 2 h |
|
Days 1–3: |
Mitoxantrone 10 mg/m2/day continuous IV infusion for 30 min |
|
Day 2: |
Intrathecal (IT) chemotherapy (Table II) |
Maintenance therapy |
Cycle 1 |
|
Cytarabine |
Days 1–3: |
Cytarabine 1 g/m2/day continuous IV infusion for 2 h |
Daunorubicin |
Days 1–3: |
Mitoxantrone 10 mg/m2/day continuous IV infusion for 30 min |
Etoposide |
Day 2: |
Intrathecal (IT) chemotherapy (Table II) |
Mitoxantrone |
Cycle 2 |
|
|
Days 1–3: |
Cytarabine 2 g/m2/day continuous IV infusion for 2 h |
|
Days 1–4: |
Etoposide 100 mg/m2/day continuous IV infusion for 1 h |
|
Day 2: |
Intrathecal (IT) chemotherapy (Table II) |
|
Cycle 3 |
|
|
Days 1–3: |
Cytarabine 3 g/m2/day continuous IV infusion for 2 h |
|
Cycle 4 |
|
|
Days 1–3: |
Cytarabine 2 g/m2/day continuous IV infusion for 2 h |
|
Days 1–4: |
Etoposide 100 mg/m2/day continuous IV infusion for 1 h |
|
Day 2: |
Intrathecal (IT) chemotherapy (Table II) |
|
Low-risk patients |
|
Induction therapy |
Cycle 1 |
|
Cytarabine |
Days 1–7: |
Cytarabine 100 mg/m2/day continuous intravenous (IV) infusion for 2 h |
Daunorubicin |
Days 1, 3 and 5: |
Daunorubicin 30 mg/m2/day continuous IV infusion for 1 h |
Etoposide |
Days 1–5: |
Etoposide 100 mg/m2/day IV for 3 h |
|
Day 2: |
Intrathecal (IT) chemotherapy (Table II) |
|
Cycle 2 |
|
|
Days 1–7: |
Cytarabine 100 mg/m2/day continuous IV infusion for 2 h |
|
Days 1, 3 and 5: |
Daunorubicin 30 mg/m2/day continuous IV infusion for 1 h |
|
Days 1–5: |
Etoposide 100 mg/m2/day continuous IV infusion for 3 h |
Maintenance therapy |
Cycle 1 |
|
Cytarabine |
Days 1–3: |
Cytarabine 1 g/m2/day continuous IV infusion for 2 h |
Daunorubicin |
Days 1–3: |
Daunorubicin 25 mg/m2/day continuous IV infusion for 1 h |
Etoposide |
Cycle 2 |
|
|
Days 1–3: |
Cytarabine 1 g/m2/day continuous IV infusion for 2 h |
|
Days 1–4: |
Etoposide 100 mg/m2/day continuous IV infusion for 1 h |
|
Cycle 3 |
|
|
Days 1–3: |
Cytarabine 2 g/m2/day continuous IV infusion for 2 h |
|
Cycle 4 |
|
|
Days 1–3: |
Cytarabine 1 g/m2/day continuous IV infusion for 2 h |
|
Days 1–4: |
Etoposide 100 mg/m2/day continuous IV infusion for 1 h |